دورية أكاديمية
Modern opportunities of interferons in treatment of children with COVID-19 ; Современные возможности интерферонов в лечении детей с COVID-19
| العنوان: | Modern opportunities of interferons in treatment of children with COVID-19 ; Современные возможности интерферонов в лечении детей с COVID-19 |
|---|---|
| المؤلفون: | Asiya Safina I., Olga Sharipova V., Ildus Lutfullin Ya., Olga Naumova S., Maria Daminova A., А. Сафина И., О. Шарипова В., И. Лутфуллин Я., О. Наумова С., М. Даминова А. |
| المصدر: | Meditsinskiy sovet = Medical Council; № 1 (2021); 59-65 ; Медицинский Совет; № 1 (2021); 59-65 ; 2658-5790 ; 2079-701X |
| بيانات النشر: | REMEDIUM GROUP Ltd. |
| سنة النشر: | 2021 |
| المجموعة: | Medical Council (E-Journal) / Медицинский Совет |
| مصطلحات موضوعية: | interferons, children, new coronavirus infection, COVID-19, SARS-CoV-2, интерфероны, дети, новая коронавирусная инфекция |
| الوصف: | Introduction. In 2020, most doctors were at the frontlines in the fight against the novel coronavirus infection (COVID-19). In the process of searching for effective etiotropic drugs, news came in that type I interferons had been successfully used for the treatment of COVID-19. Choosing the optimal COVID-19 treatment strategy is of pivotal importance for vulnerable populations such as children.Objective of the study. To show our own experience in providing medical care to children with COVID-19 and present the results of a comparative study of the efficacy and safety of interferon alfa-2b drugs combined with highly active antioxidants in the complex COVID-19 therapy in children.Materials and methods. A comparative study of the efficacy and safety of interferon alfa-2b drugs combined with highly active antioxidants in the complex COVID-19 therapy in children was conducted. The study included children with a laboratoryconfirmed diagnosis of COVID-19 aged 1 – 17 years (n = 85). In the treatment group (n = 45), children received interferon alfa-2b drugs such as VIFERON® rectal suppositories and VIFERON® gel for topical administration according to the dosage regimen and standard therapy. In the control group (n = 40), children only received standard therapy in accordance with the recommendations of the Ministry of Health of Russia.Results and discussion. 3,696 patients, including 3,507 children, received medical care in the City Children’s Hospital No. 1 in Kazan since April 2020. The share of laboratory-confirmed COVID-19 cases among admitted children was 21% (n = 736), of which 85 were enrolled in the study to assess the efficacy of complex therapy with interferon alpha-2b drugs combined with highly active antioxidants. The interferon alfa-2b therapy of COVID-19 children reduced the duration of the key clinical symptoms of the disease by 1.5-4 days and the virus elimination time by 6 days.Conclusions. The use of interferon alfa-2b VIFERON® rectal suppositories and VIFERON® gel for topical administration according ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | Russian |
| العلاقة: | https://www.med-sovet.pro/jour/article/view/6028/5498Test; Александрович Ю.С., Байбарина Е.Н., Баранов А.А., Вишнева Е.А., Зверева Н.Н., Иванов Д.О. и др. Особенности клинических проявлений и лечения заболевания, вызванного новой коронавирусной инфекцией (COVID19) у детей. Версия 1 (24.04.2020).М.; 2020. 43 с. Режим доступа: https://static-3.rosminzdrav.ru/system/attachments/attaches/000/050/100/original/24042020_child_COVID-19_1_Final.pdfTest.; Александрович Ю.С., Алексеева Е.И., Бакрадзе М.Д., Баранов А.А., Батышева Т.Т., Вашакмадзе Н.Д. и др. Особенности клинических проявлений и лечения заболевания, вызванного новой коронавирусной инфекцией (COVID19) у детей. Версия 2 (03.07.2020).М.; 2020. 73 с. Режим доступа: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/050/914/original/03062020_%D0%B4%D0%B5%D1%82%D0%B8_COVID-19_v2.pdfTest.; Park A., Iwasaki A. Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19. Cell Host Microbe.2020;27(6):870–878. doi:10.1016/j.chom.2020.05.008.; Zhou Q., Chen V., Shannon C.P., Wei X.S., Xiang X., Wang X. et al. Interferon-α2b Treatment for COVID-19. Front Immunol.2020;11:1061.doi:10.3389/fimmu.2020.01061.; Busnadiego I., Fernbach S., Pohl M.O., Karakus U., Huber M., Trkola A. et al. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2. mBio. 2020;11(5):e01928–20. doi:10.1128/mBio.01928-20.; Walter M.R. The Role of Structure in the Biology of Interferon Signaling. Front Immunol. 2020;11:606489. doi:10.3389/fimmu.2020.606489.; Shen K., Yang Y., Wang T., Zhao D., Jiang Y., Jin R. et al. Diagnosis, Treatment, and Prevention of 2019 Novel Coronavirus Infection in Children: Experts’ Consen sus Statement. World J Pediatr. 2020;16(3):223–231. doi:10.1007/s12519-020-00343-7.; Сафина А.И., Закиров И.И., Лутфуллин И.Я., Волянюк Е.В., Даминова М.А. COVID-19 в детском возрасте: о чем говорит накопленный опыт? Российский вестник перинатологии и педиатрии.2020;65(5):193–197. doi:10.21508/1027-4065-2020-65-5-193-197.; https://www.med-sovet.pro/jour/article/view/6028Test |
| DOI: | 10.21518/2079-701X-2021-1-59-65 |
| الإتاحة: | https://doi.org/10.21518/2079-701X-2021-1-59-65Test https://doi.org/10.1016/j.chom.2020.05.008Test https://doi.org/10.3389/fimmu.2020.01061Test https://doi.org/10.1128/mBio.01928-20Test https://doi.org/10.3389/fimmu.2020.606489Test https://doi.org/10.1007/s12519-020-00343-7Test https://www.med-sovet.pro/jour/article/view/6028Test |
| حقوق: | Authors publishing their articles in this journal shall agree to the following:Authors reserve the copyright to the work and grant the journal a license to publish the work for the first time Creative Commons Attribution License (CC BY), which allows other persons to distribute this work with the obligatory preservation of references to the authors of the original work and the original publication in this journal.Authors reserve the right to conclude separate contractual arrangements regarding the non-exclusive distribution of the work version in the form published here (for example, posting it in the institute’s repository, publication in a book), with reference to its original publication in this journal.Authors have the right to post work on the Internet (for example, in the institute’s repository or personal website) before and during the process of considering it by this journal, as this can result in a productive discussion and more references to this work. ; Авторы, публикующие в данном журнале, соглашаются со следующим:Авторы сохраняют за собой авторские права на работу и предоставляют журналу право первой публикации работы на условиях лицензии Creative Commons Attribution License, которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в журнале.Авторы сохраняют право заключать отдельные контрактные договорённости, касающиеся не-эксклюзивного распространения версии работы в опубликованном виде (например, размещение ее в институтском хранилище, публикацию в книге), со ссылкой на ее оригинальную публикацию.Авторы имеют право размещать работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу. (См. The Effect of Open Access). |
| رقم الانضمام: | edsbas.A83401C3 |
| قاعدة البيانات: | BASE |
| DOI: | 10.21518/2079-701X-2021-1-59-65 |
|---|